公开(公告)号：WO2004014313A2

公开(公告)日：2004-02-19

申请号：PCT/US2003/025036

申请日：2003-08-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  COLONNO, Richard ,  LEMM, Julie ,  O'BOYLE, Donald ,  GAO, Min ,  ROMINE, Jeffrey, Lee ,  MARTIN, Scott, W. ,  SNYDER, Lawrence, B. ,  SERRANO-WU, Michael ,  DESHPANDE, Milind ,  WHITEHOUSE, Darren

Inventor： COLONNO, Richard ,  LEMM, Julie ,  O'BOYLE, Donald ,  GAO, Min ,  ROMINE, Jeffrey, Lee ,  MARTIN, Scott, W. ,  SNYDER, Lawrence, B. ,  SERRANO-WU, Michael ,  DESHPANDE, Milind ,  WHITEHOUSE, Darren

IPC: A61K

CPC classification number: C07D417/04 ,  A61K31/00 ,  A61K31/426 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/208 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07D277/42 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04 ,  A61K2300/00

Abstract: Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound effective to inhibit the function of the HCV NS5A protein and another compound having anti-HCV activity. Compounds which can inhibit the function of the NS5A protein having the structure of formula (I) are described; wherein R, R', R 1 , R 2 , and R 3 are as defined in the specification. The other compounds having anti-HCV activity are effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.

Abstract translation: 公开了用于治疗HCV感染的组合药剂，其包含有效抑制HCV NS5A蛋白的功能的化合物和另一种具有抗HCV活性的化合物。 描述了可以抑制具有式（I）结构的NS5A蛋白的功能的化合物; 其中R，R'，R 1，R 2和R 3如说明书中所定义。 具有抗HCV活性的其它化合物可有效抑制选自HCV金属蛋白酶，HCV丝氨酸蛋白酶，HCV聚合酶，HCV解旋酶，HCV NS4B蛋白，HCV进入，HCV组装，HCV出血，HCV NS5A蛋白，IMPDH和用于治疗HCV感染的核苷类似物。

公开(公告)号：WO2009023487A1

公开(公告)日：2009-02-19

申请号：PCT/US2008/072295

申请日：2008-08-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  BERGSTROM, Carl, P. ,  MARTIN, Scott, W.

Inventor： BERGSTROM, Carl, P. ,  MARTIN, Scott, W.

IPC: C07D487/04 ,  C07D519/00 ,  A61K31/55 ,  A61P31/14

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Abstract translation: 本发明包括式I化合物以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：WO2007092000A1

公开(公告)日：2007-08-16

申请号：PCT/US2006/004156

申请日：2006-02-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  HUDYMA, Thomas, W. ,  ZHENG, Xiaofan ,  HE, Feng ,  DING, Min ,  BERGSTROM, Carl, P. ,  HEWAWASAM, Piyasena ,  MARTIN, Scott, W. ,  GENTLES, Robert, G.

Inventor： HUDYMA, Thomas, W. ,  ZHENG, Xiaofan ,  HE, Feng ,  DING, Min ,  BERGSTROM, Carl, P. ,  HEWAWASAM, Piyasena ,  MARTIN, Scott, W. ,  GENTLES, Robert, G.

IPC: C07D487/04 ,  C07D471/04 ,  C07D491/14 ,  C07D403/04 ,  A61K31/55 ,  A61P31/14

CPC classification number: C07D471/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/14 ,  C07D491/14 ,  C07D513/14

Abstract: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds. (I)

Abstract translation: 描述式I的吲哚化合物。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。 还描述了包含化合物的不同形式和组合物以及制备化合物的方法。 （一世）

公开(公告)号：WO2005034850A3

公开(公告)日：2005-04-21

申请号：PCT/US2004/027533

申请日：2004-08-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  GLUNZ, Peter, W. ,  DOUTY, Brent, D. ,  MARTIN, Scott, W. ,  ROMINE, Jeffrey

Inventor： GLUNZ, Peter, W. ,  DOUTY, Brent, D. ,  MARTIN, Scott, W. ,  ROMINE, Jeffrey

IPC: A61K31/41

Abstract: Compounds of Formula (I) are disclosed which inhibit hepatitis C NS5B RNA-dependent RNA polymerase and are useful for treating hepatitis C. Compositions and methods of using these compounds are also disclosed.

公开(公告)号：WO2004014852A2

公开(公告)日：2004-02-19

申请号：PCT/US2003/024717

申请日：2003-08-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  ROMINE, Jeffrey, Lee ,  MARTIN, Scott, W. ,  SNYDER, Lawrence, B. ,  SERRANO-WU, Michael ,  DESHPANDE, Milind ,  WHITEHOUSE, Darren ,  LEMM, Julie ,  O'BOYLE, Donald ,  GAO, Min ,  COLONNO, Richard

Inventor： ROMINE, Jeffrey, Lee ,  MARTIN, Scott, W. ,  SNYDER, Lawrence, B. ,  SERRANO-WU, Michael ,  DESHPANDE, Milind ,  WHITEHOUSE, Darren ,  LEMM, Julie ,  O'BOYLE, Donald ,  GAO, Min ,  COLONNO, Richard

IPC: C07D

CPC classification number: C07D417/04 ,  A61K31/00 ,  A61K31/426 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/208 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07D277/42 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04 ,  A61K2300/00

Abstract: Compounds having the structure of formula I are described (I) wherein R, R', R1, R2, and R3 are as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.

Abstract translation: 具有式I结构的化合物描述于（I）中，其中R，R'，R 1，R 2和R 3如说明书中所定义。 这些化合物可以抑制丙型肝炎病毒（HCV）复制，特别是HCV NS5A蛋白的功能。

公开(公告)号：WO1998004135A1

公开(公告)日：1998-02-05

申请号：PCT/US1997014352

申请日：1997-07-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： BRISTOL-MYERS SQUIBB COMPANY ,  ROMINE, Jeffrey, L. ,  MARTIN, Scott, W. ,  HEWAWASAM, Piyasena ,  MEANWELL, Nicholas, A. ,  GRIBKOFF, Valentin, K. ,  STARRETT, John, E., Jr.

IPC: A01N43/653

CPC classification number: C07D263/58 ,  C07D233/64 ,  C07D233/70 ,  C07D233/76 ,  C07D235/12 ,  C07D249/12 ,  C07D249/14 ,  C07D271/113 ,  C07D413/10

Abstract: Novel compounds of formula (1) are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels, wherein "Het" is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; R , R and R each are independently selected from hydrogen, halogen, OH, CF3, NO2, or (a); provided R is not hydrogen; and when R and R are hydrogen, R may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; R and R each are independently selected form hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and R and R each are independently hydrogen; C1-4 alkyl; or R and R , taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.

Abstract translation: 式（1）的新型化合物可用于治疗对大电导钙激活钾通道的开放物起反应的病症，其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a，R b和R c各自独立地选自氢，卤素，OH，CF 3，NO 2或（a）; 条件是R c不是氢; 当R a和R b为氢时，R c可以是选自咪唑-1-基，吗啉代甲基，N-甲基咪唑-2-基和吡啶-2-基的杂环部分， 基; R d和R e各自独立地选自氢，卤素，CF 3，NO 2或咪唑-1-基; m，n和p各自独立地选自0或1的整数; 和R f和R g各自独立地为氢; C 1-4烷基; 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪，吗啉，硫代吗啉，N-苄基哌嗪和咪唑啉酮的杂环部分。

公开(公告)号：WO2007092888A3

公开(公告)日：2007-08-16

申请号：PCT/US2007/061768

申请日：2007-02-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  BERGSTROM, Carl, P. ,  MARTIN, Scott, W. ,  HUDYMA, Thomas, W.

Inventor： BERGSTROM, Carl, P. ,  MARTIN, Scott, W. ,  HUDYMA, Thomas, W.

IPC: C07D487/04 ,  A61K31/55 ,  A61P31/12

Abstract: The invention encompasses compounds of Formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

公开(公告)号：WO2007033175A1

公开(公告)日：2007-03-22

申请号：PCT/US2006/035490

申请日：2006-09-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  BERGSTROM, Carl, P. ,  BENDER, John, A. ,  GENTLES, Robert, G. ,  HEWAWASAM, Piyasena ,  HUDYMA, Thomas, W. ,  KADOW, John, F. ,  MARTIN, Scott, W. ,  REGUEIRO-REN, Alicia ,  YEUNG, Kap-Sun ,  TU, Yong ,  GRANT-YOUNG, Katharine, A. ,  ZHENG, Xiaofan

Inventor： BERGSTROM, Carl, P. ,  BENDER, John, A. ,  GENTLES, Robert, G. ,  HEWAWASAM, Piyasena ,  HUDYMA, Thomas, W. ,  KADOW, John, F. ,  MARTIN, Scott, W. ,  REGUEIRO-REN, Alicia ,  YEUNG, Kap-Sun ,  TU, Yong ,  GRANT-YOUNG, Katharine, A. ,  ZHENG, Xiaofan

IPC: C07D487/04 ,  A61K31/55 ,  A61P31/14

CPC classification number: C07D491/14 ,  C07D487/04

Abstract: The invention encompasses compounds and salts of Formulas (I), (II), (III), and (IV) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Abstract translation: 本发明包括式（I），（II），（III）和（IV）的化合物和盐以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：WO2010093359A1

公开(公告)日：2010-08-19

申请号：PCT/US2009/033801

申请日：2009-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  MARTIN, Scott, W. ,  BERGSTROM, Carl P. ,  GENTLES, Robert G. ,  YEUNG, Kap-Sun

Inventor： MARTIN, Scott, W. ,  BERGSTROM, Carl P. ,  GENTLES, Robert G. ,  YEUNG, Kap-Sun

IPC: C07D487/04 ,  A61K31/55 ,  A61P31/14

CPC classification number: C07D487/04

Abstract: The invention encompasses selected compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Abstract translation: 本发明包括选择的式I化合物以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：WO2006020082A1

公开(公告)日：2006-02-23

申请号：PCT/US2005/025234

申请日：2005-07-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  HUDYMA, Thomas, W. ,  ZHENG, Xiaofan ,  HE, Feng ,  DING, Min ,  BERGSTROM, Carl, P. ,  HEWAWASAM, Piyasena ,  MARTIN, Scott, W. ,  GENTLES, Robert, G.

Inventor： HUDYMA, Thomas, W. ,  ZHENG, Xiaofan ,  HE, Feng ,  DING, Min ,  BERGSTROM, Carl, P. ,  HEWAWASAM, Piyasena ,  MARTIN, Scott, W. ,  GENTLES, Robert, G.

IPC: C07D491/14 ,  C07D487/04 ,  C07D498/14 ,  C07D471/14 ,  C07D471/04 ,  C07D487/14 ,  C07D513/14 ,  A61K31/55 ,  A61P31/14

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D487/14 ,  C07D491/14 ,  C07D513/14

Abstract: Indole compounds of Formula (I) are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

Abstract translation: 描述了式（I）的吲哚化合物。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。 还描述了包含化合物的不同形式和组合物以及制备化合物的方法。